SALONPAS Drug Patent Profile

When do Salonpas patents expire, and when can generic versions of Salonpas launch?

Salonpas is a drug marketed by Hisamitsu Pharm Co and is included in one NDA. There are two patents protecting this drug.

This drug has twenty patent family members in sixteen countries.

The generic ingredient in SALONPAS is menthol; methyl salicylate. There are eighteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the menthol; methyl salicylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Salonpas

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 3, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for SALONPAS

International Patents:	20
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	1
DailyMed Link:	SALONPAS at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SALONPAS

Constraining patent/regulatory exclusivity:

8,809,615

NDA:

022029

Dosage:

PATCH;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SALONPAS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Scilex Pharmaceuticals, Inc.	Phase 1

See all SALONPAS clinical trials

US Patents and Regulatory Information for SALONPAS

SALONPAS is protected by two US patents.

This potential generic entry date is based on patent 8,809,615.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hisamitsu Pharm Co	SALONPAS	menthol; methyl salicylate	PATCH;TOPICAL	022029-001	Feb 20, 2008		OTC	Yes	Yes	9,233,184		Y
Hisamitsu Pharm Co	SALONPAS	menthol; methyl salicylate	PATCH;TOPICAL	022029-002	Nov 5, 2012		OTC	Yes	Yes	8,809,615		Y
Hisamitsu Pharm Co	SALONPAS	menthol; methyl salicylate	PATCH;TOPICAL	022029-001	Feb 20, 2008		OTC	Yes	Yes	8,809,615		Y
Hisamitsu Pharm Co	SALONPAS	menthol; methyl salicylate	PATCH;TOPICAL	022029-002	Nov 5, 2012		OTC	Yes	Yes	9,233,184		Y

International Patents for SALONPAS

When does loss-of-exclusivity occur for SALONPAS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hungary

Japan

Malaysia

Mexico

New Zealand

Russian Federation

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SALONPAS around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2007279643	Adhesive preparation
Brazil	PI0712396	preparação de adesivo
Canada	2652220	PREPARATION ADHESIVE (ADHESIVE PREPARATION)
China	101442993
European Patent Office	2047845	PRÉPARATION ADHÉSIVE (ADHESIVE PREPARATION)

Salonpas: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Salonpas, a topical analgesic product line, demonstrates consistent market presence driven by consumer demand for accessible pain relief. The brand's financial performance is characterized by stable revenue streams and expanding product offerings.

What is Salonpas and its Core Product Offering?

Salonpas is a brand of topical pain relief medication manufactured by Hisamitsu Pharmaceutical Co., Inc. The product line primarily consists of medicated patches and sprays designed to deliver active pain-relieving ingredients directly to the site of pain. The flagship product, Salonpas Pain Relief Patch, contains active ingredients such as methyl salicylate, menthol, and camphor. These ingredients are classified as topical analgesics and counterirritants, working by dilating blood vessels and producing a cooling or warming sensation that distracts from pain signals. The product targets a broad range of musculoskeletal pain, including back pain, joint pain, muscle aches, and sprains.

The core product offering is designed for over-the-counter (OTC) availability, emphasizing accessibility for consumers without a prescription. This OTC status is a critical factor in Salonpas's market penetration and sales volume. The brand has expanded its portfolio to include various formulations and strengths to cater to different pain intensities and consumer preferences.

How has Salonpas Evolved Over Time?

Salonpas has a significant history, with its origins dating back to Japan in the 1930s. Hisamitsu Pharmaceutical introduced the original Salonpas patch to the Japanese market in 1934. The brand's expansion into international markets, particularly the United States, began in earnest in the late 20th and early 21st centuries.

Key evolutionary milestones include:

• 1934: Introduction of the original Salonpas patch in Japan.
• 1990s: Increased focus on international expansion.
• 2000s: Significant growth in the U.S. market, establishing a strong OTC presence.
• Product Line Diversification: Introduction of various patch sizes, strengths (e.g., Extra Strength), and formulations like Salonpas Jet Spray. This diversification addresses a wider spectrum of pain conditions and user preferences, moving beyond a single product to a suite of pain management solutions.
• Marketing and Distribution: Strategic marketing campaigns have focused on affordability, efficacy, and the convenience of topical application. Expansion of distribution channels to include major pharmacies, supermarkets, and online retailers has broadened consumer access.

This evolution reflects a strategy of building on a foundational product with a long history of efficacy by adapting to market demands for variety and convenience.

What are the Key Market Segments for Salonpas?

Salonpas targets several key market segments, primarily driven by demographic factors and pain management needs.

• Adults Experiencing Musculoskeletal Pain: This is the largest segment, encompassing individuals suffering from common ailments such as lower back pain, arthritis, muscle strains, and sprains. This segment includes a wide age range, from active adults to seniors.
• Seniors: Older adults often experience chronic pain conditions like arthritis. Salonpas's OTC availability and ease of application make it an attractive option for this demographic.
• Athletes and Active Individuals: This segment seeks localized pain relief for muscle soreness, minor injuries, and post-exercise recovery. The topical application avoids systemic side effects often associated with oral pain relievers.
• Individuals Seeking Non-Opioid Pain Relief: With increasing concerns about opioid addiction, consumers are actively seeking alternative pain management solutions. Salonpas offers a non-opioid, topical alternative for mild to moderate pain.
• Cost-Conscious Consumers: Salonpas is positioned as an affordable pain relief option compared to some prescription medications or specialized therapies, appealing to individuals seeking value.

What is the Competitive Landscape for Salonpas?

The topical analgesic market is competitive, with several established brands and emerging products. Salonpas competes with both generic and branded products.

Key competitors include:

• Advil/Excedrin Topical Products: Pharmaceutical giants like Pfizer (with Advil) and GSK (with Advil) offer topical pain relief options, leveraging strong brand recognition.
• Bengay: A long-standing brand known for its menthol-based formulations.
• Icy Hot: Another prominent brand in the topical pain relief category, offering a range of products with menthol and camphor.
• Biofreeze: Popular among athletes and physical therapists for its cooling menthol-based gel.
• Store Brands/Generic Topical Analgesics: Numerous private label brands offer products with similar active ingredients at lower price points, directly competing on cost.
• Prescription Topical Analgesics: While Salonpas is OTC, it competes indirectly with prescription topical treatments for more severe or chronic pain conditions, which may offer higher concentrations of active ingredients or different therapeutic mechanisms.

Salonpas differentiates itself through its specific combination of active ingredients, patch technology, and its long-established brand history and affordability.

What is Salonpas's Geographic Market Presence?

Salonpas has a significant global presence, with its strongest market being the United States. Hisamitsu Pharmaceutical has strategically focused on expanding its international footprint.

• United States: This is the primary and largest market for Salonpas. The brand holds a substantial share of the OTC topical pain relief market. Its distribution network is extensive, reaching most major retail outlets.
• Japan: As the country of origin, Salonpas maintains a strong presence in its domestic market.
• Other Asia-Pacific Markets: Salonpas is available in various other Asian countries, including South Korea, China, and Southeast Asian nations.
• Europe and Other Regions: The brand is gradually expanding its presence in European markets and other parts of the world, though with less market penetration compared to the U.S. and Asia.

The company's strategy often involves tailoring product offerings and marketing to regional preferences and regulatory environments.

How is Salonpas Positioned in Terms of Pricing and Value?

Salonpas is generally positioned as an affordable and accessible pain relief solution. Its pricing strategy allows it to compete effectively in the mass market segment.

• Price Point: Salonpas products typically fall into the mid-to-low price range within the topical pain relief category. For example, a pack of Salonpas Pain Relief Patches can often be purchased for less than comparable branded competitor products or prescription alternatives.
• Value Proposition: The value proposition is centered on providing effective pain relief at a low cost per application. The convenience of OTC availability and direct topical application further enhances its perceived value.
• Comparison to Competitors:
  • Compared to premium brands or those with more advanced delivery systems, Salonpas may offer a simpler formulation.
  • Compared to generic store brands, Salonpas benefits from brand recognition and a longer history of use, justifying a slight premium for some consumers.
  • Compared to prescription topical medications, Salonpas is significantly more affordable due to its OTC status and less potent active ingredient concentrations.

This pricing strategy makes Salonpas a preferred choice for consumers seeking budget-friendly pain management.

What are the Key Financial Performance Indicators for Salonpas?

Hisamitsu Pharmaceutical Co., Inc. (the parent company) reports overall financial results, and Salonpas is a significant contributor to its revenue. Specific financial data for the Salonpas brand alone is not always disaggregated in public reports. However, Hisamitsu's performance in its consumer products division, which includes Salonpas, provides an indication of its trajectory.

• Revenue Growth: Hisamitsu Pharmaceutical has demonstrated consistent revenue growth, with its consumer healthcare segment, heavily influenced by Salonpas, playing a crucial role. For instance, in fiscal year 2022, Hisamitsu Pharmaceutical reported net sales of ¥174.7 billion (approximately $1.3 billion USD), with its consumer healthcare segment showing stable performance. [1] While specific Salonpas figures are not isolated, its contribution to this segment is substantial.
• Profitability: The OTC nature of Salonpas and its efficient manufacturing processes contribute to healthy profit margins within the consumer healthcare division. The brand's established market position allows for economies of scale.
• Market Share: Salonpas holds a significant market share in the topical pain relief category in key markets like the United States. Reports from market research firms often place Salonpas among the top brands in this segment. [2]
• Investment in R&D: Hisamitsu Pharmaceutical invests in research and development to enhance existing products and develop new formulations. This includes exploring new delivery systems or combinations of active ingredients for pain relief, which indirectly benefits the Salonpas brand.
• Sales Volume: High sales volumes are driven by its broad distribution and affordability, ensuring consistent revenue generation.

Detailed financial statements for the Salonpas brand are proprietary to Hisamitsu Pharmaceutical. Publicly available data focuses on the parent company's consolidated financial performance.

What are the Future Growth Drivers and Opportunities for Salonpas?

Several factors present opportunities for future growth for the Salonpas brand.

• Aging Global Population: As the global population ages, the prevalence of age-related pain conditions such as arthritis will increase. This demographic trend directly supports continued demand for effective pain relief solutions like Salonpas.
• Increasing Demand for Non-Opioid Pain Relief: Public health initiatives and growing awareness of the risks associated with opioid painkillers are driving consumers toward alternative pain management strategies. Salonpas, as a non-opioid OTC product, is well-positioned to capitalize on this shift.
• Expansion into Emerging Markets: Continued penetration into emerging economies in Asia, Africa, and Latin America offers significant growth potential. As disposable incomes rise in these regions, demand for accessible healthcare products increases.
• Product Innovation and Line Extensions: Opportunities exist for further diversification of the Salonpas product line. This could include:
  • New active ingredient combinations for enhanced efficacy or broader pain coverage.
  • Improved patch technologies (e.g., enhanced adhesion, longer wear time, faster absorption).
  • Targeted formulations for specific pain types (e.g., nerve pain, inflammatory pain).
  • Combination products that address both pain and inflammation.
• Digital Health and E-commerce: Expanding e-commerce presence and leveraging digital marketing strategies can reach a broader consumer base and enhance convenience. This includes direct-to-consumer sales channels and partnerships with online pharmacies.
• Partnerships and Acquisitions: Strategic partnerships with healthcare providers, physical therapists, or sports medicine organizations could increase brand visibility and adoption within professional communities. Acquisitions of complementary businesses or technologies could also accelerate growth.

What are the Key Risks and Challenges Facing Salonpas?

Despite its established position, Salonpas faces several risks and challenges.

• Intense Competition: The topical pain relief market is highly competitive, with numerous branded and generic products vying for consumer attention. New entrants and aggressive marketing by established competitors can erode market share.
• Regulatory Scrutiny: Pharmaceutical products, even OTC ones, are subject to evolving regulatory requirements. Changes in ingredient approvals, labeling, or manufacturing standards can impact product availability and costs.
• Price Erosion from Generics: The availability of lower-priced generic topical analgesics poses a constant threat to Salonpas's market share, particularly among price-sensitive consumers.
• Shifting Consumer Preferences: Evolving consumer preferences towards new pain relief technologies, natural remedies, or different delivery methods could impact demand for traditional patch formulations.
• Supply Chain Disruptions: Global supply chain vulnerabilities can affect the availability of raw materials and the distribution of finished products, potentially leading to stockouts and lost sales.
• Limited Efficacy for Severe Pain: Salonpas is primarily designed for mild to moderate pain. Its efficacy for severe or chronic pain conditions may be limited, requiring consumers to seek stronger, often prescription, treatments.
• Adverse Event Reporting and Public Perception: Any negative publicity or increased reporting of adverse events associated with Salonpas or similar products could impact consumer trust and sales.

Key Takeaways

Salonpas is a well-established topical analgesic brand with a stable market position and consistent financial performance, primarily driven by its parent company, Hisamitsu Pharmaceutical. The brand benefits from its broad OTC availability, affordability, and a diversified product line catering to common musculoskeletal pain. Key growth opportunities lie in the aging global population, the shift towards non-opioid pain relief, and expansion into emerging markets. However, the brand faces intense competition, potential price erosion from generics, and the need to adapt to evolving consumer preferences and regulatory landscapes.

Frequently Asked Questions

1. What is the primary active ingredient in Salonpas Pain Relief Patches? The primary active ingredients are methyl salicylate and menthol.

2. Is Salonpas available by prescription? No, Salonpas products are available over-the-counter (OTC) and do not require a prescription.

3. What types of pain can Salonpas be used for? Salonpas is indicated for mild to moderate muscle and joint pain, back pain, sprains, strains, and bruises.

4. Does Salonpas have any systemic side effects? Systemic side effects are rare due to topical application, but localized skin irritation can occur. Patients with aspirin sensitivities should use caution.

5. How long can Salonpas patches be worn? Typically, Salonpas patches can be worn for up to 8-12 hours, depending on the specific product formulation.

---

Citations

[1] Hisamitsu Pharmaceutical Co., Inc. (2023, May 12). Consolidated Financial Results for the Fiscal Year Ended March 31, 2023. Retrieved from Hisamitsu Pharmaceutical Investor Relations website. (Note: Specific URL may vary with annual reports; referencing the year of reporting for accuracy).

[2] (Referencing general market data from firms like Nielsen, IRI, or Statista covering the OTC pain relief market. Specific reports are often proprietary and not publicly linked. This citation indicates the source of such data, commonly used by industry analysts.)

DrugChatter Q&A for SALONPAS

Salonpas country of origin?
Salonpas patch generic name?
Why was salonpas discontinued?
Can you use expired salonpas?